Zhaoke Ophthalmology (6622.HK) completed HK IPO
We are pleased to announce that our invested company Zhaoke Ophthalmology Limited (the “Company”) completed its IPO on the Hong Kong Stock Exchange today.
VMS Securities Limited (the securities subsidiary of VMS Group) was a joint-bookrunner and VMS Healthcare SPC – VMS Zhaoke Investment Fund SP was a cornerstone investor of the Company’s IPO.
VMS has been working closely with the Company since the Series A financing investment in June 2019 and assisted the Company to establish its in-licensed product pipeline. We firmly entrenched a long term positive view towards the Company and adhered our investment via its series B financing in November 2020.
The Company is an ophthalmic pharmaceutical company dedicated to the discovery, development and commercialization of therapies that address significant unmet medical needs in China. Leveraging on its deep domain expertise, the Company has built a comprehensive ophthalmic drug pipeline of 25 candidates that cover most major ocular indications affecting the front and the back of an eye. It has also established a state-of-the-art ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of near-term product launches. Its goal is to become a leader in China and the neighboring ASEAN marketplace.
From Left to Right: Alva Chen (VP of VMS PE Healthcare), Andrew Ng (MD and Head of VMS PE Healthcare), Dr. Li Xiaoyi (Chairman and CEO of Zhaoke), Benny Chong (Chairman of VMS Group) and Jerry Tsoi (Associate of VMS PE Healthcare)
VMS has been focusing on Healthcare investment since 2017, leading by Andrew Ng, Managing Director and Head of Healthcare of VMS Asset Management. We comprise hybrid vigor and expertise on Healthcare sectors, exploring an intrinsic value for distinctive investments within the sector. The investments in portfolio companies New Horizon Health (6606.HK), Pharmaron (300759.CH), Zhaoke (6622.HK), KingMed (603882.CH), i-Mab (IMAB.US), Chemclin (688468.CH), CareRay (688607.CH) and Gamida Cell (GMDA.US) have already proven our commitment and we believe this diversity will seize more investment landscapes for our investors.
If you would like to hear the latest updates on the Firm and the Fund, please feel free to contact our Investor Relations team at IR@VMSIG.COM.